Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Lung Cancer. 2018 May 1;121:82–90. doi: 10.1016/j.lungcan.2018.04.024

Fig. 2. The levels of HIF-1α and c-Jun are increased in NSCLC cells with acquired resistance to gefitinib.

Fig. 2

A. HCC827R and H3255RR cells were treated with the indicated concentrations of gefitinib for 5 days. Cell survival was measured by MTT proliferation assay. B. HCC827, HCC827R, H3255 and H3255RR cells were treated with 20 nM gefitinib or DMSO vehicle control for 24 hours. Cells were then harvested, and equal amounts of protein lysates were subjected to Western blot analysis with the indicated antibodies. The level of β-actin was used as a reference of lysate protein loading control of each cell line.